Medicus Pharma Clarifies Positive SkinJect Phase 2 Results

Company focuses on drug-driven efficacy, plans registrational strategy for 200μg dose

Apr. 2, 2026 at 1:03am

Got story updates? Submit your updates here. ›

Medicus Pharma Ltd. issued a clarification regarding the topline results from its Phase 2 clinical study of SkinJect, an investigational doxorubicin-containing microneedle array, in nodular basal cell carcinoma. The company noted that the device-only arm provided useful mechanistic context, but the development focus is on the performance of the active treatment arms to advance SkinJect to a registrational study. The 200μg dose cohort demonstrated the highest observed activity and will be the basis of the planned registrational strategy.

Why it matters

If confirmed in future studies, SkinJect may offer a meaningful non-surgical treatment option for patients with nodular basal cell carcinoma, a common form of skin cancer currently treated primarily with surgery. The positive Phase 2 results support the therapeutic value of SkinJect and establish the best path forward towards a registrational study.

The details

The Phase 2 study included a microneedle device-only arm, which did not contain active drug and was incorporated to provide scientific and mechanistic context. However, the company's development focus is on the performance of the active treatment arms containing the doxorubicin-containing microneedle array (D-MNA). The 200μg dose cohort demonstrated the highest observed activity, with 73% clinical clearance and 40% histological response at Day 57 post-treatment. Based on these findings, the planned registrational development strategy will focus on the 200μg dose regimen, looking to refine the study design, endpoints, and biopsy timing.

  • The Phase 2 study topline results were originally announced on March 5, 2026.
  • Medicus plans to participate in an End-of-Phase 2 meeting with the FDA in the first half of 2026.

The players

Medicus Pharma Ltd.

A biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, including the SkinJect investigational doxorubicin-containing microneedle array.

Dr. Raza Bokhari

Executive Chairman and CEO of Medicus Pharma Ltd.

Carolyn Bonner

President and Chief Financial Officer of Medicus Pharma Ltd.

Anna Baran-Djokovic

SVP Investor Relations at Medicus Pharma Ltd.

Got photos? Submit your photos here. ›

What they’re saying

“We believe the positive topline results from 200 ug cohort at day 57, support the therapeutic value of SkinJect and establishes the best path forward towards registrational study.”

— Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma Ltd.

What’s next

Medicus plans to participate in an End-of-Phase 2 meeting with the FDA in the first half of 2026 to align on the registrational strategy focused on the 200μg dose regimen.

The takeaway

The positive Phase 2 results for Medicus Pharma's SkinJect investigational therapy demonstrate the potential for a non-surgical treatment option for patients with nodular basal cell carcinoma, a common form of skin cancer. The company's focus on the 200μg dose regimen positions SkinJect for advancement towards a registrational study and potential regulatory approval.